scholarly journals Transthyretin Amyloidosis in Aged Vervet Monkeys, as a Candidate for the Spontaneous Animal Model of Senile Systemic Amyloidosis

10.5772/19111 ◽  
2011 ◽  
Author(s):  
Shinichiro Nakamura ◽  
Mitsuharu Ueda ◽  
Naohide Ageyama ◽  
Yukio Ando ◽  
Ryuzo Torii
Keyword(s):  
Animal Model ◽  
Systemic Amyloidosis ◽  
Vervet Monkeys ◽  
Transthyretin Amyloidosis ◽  
Senile Systemic Amyloidosis ◽  
Spontaneous Animal Model

Amiloidosi da transtiretina (ATTR): l’altra faccia della medaglia

2019 ◽  
Vol 31 (1) ◽  
pp. 12-21
Author(s):  
Federico Perfetto ◽  
Francesco Cappelli ◽  
Silvia Farsetti ◽  
Elio Dimarcantonio ◽  
Silvia Casagrande ◽  
...  
Keyword(s):  
Messenger Rna ◽  
Amyloid Fibrils ◽  
Clinical Symptoms ◽  
Systemic Amyloidosis ◽  
Transthyretin Amyloidosis ◽  
Senile Systemic Amyloidosis ◽  
Intact Molecule ◽  
Total Body ◽  
The Many ◽  
Therapeutic Alternatives

Transthyretin amyloidosis (ATTR) is becoming an emerging clinical entity, and is currently the most common form of systemic amyloidosis. ATTR consists of two distinct diseases depending on whether the amyloid fibrils derive from the intact molecule of TTR (ATTR wild-type or senile systemic amyloidosis) or from different mutations occurred in the TTR molecule gene (ATTRm). Total-body scintigraphy with diphosphonates has greatly improved the diagnosis in patients with isolated cardiac involvement for both ATTRm and ATTRwt, thus avoiding the need of endomiocardial biopsy in cases without serum and/or urinary monoclonal component (MC). Heart failure alone, or associated with peripheral and autonomic neuropathy, are the main clinical symptoms in these patients. Particular attention must be paid in order to exclude hypertrophic cardiomiopathy or light chain (AL) forms in patients with MC. Today, besides hepatic transplantation, which is almost reserved to patients with early Val30Met neuropathy, many new therapeutic alternatives can be offered to these patients. Tafamidis, a TTR-stabilizer that has recently proved to be effective in cardiac forms of both ATTRm and ATTRwt, is now ready for clinical use. In addition, drugs silencing the TTR messenger RNA should soon be available for treatment. The many therapeutic opportunities available today for ATTR, strenghten even more the need for an early diagnosis of the disease both in ATTRm and ATTRwt.

scholarly journals Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy

Amyloid ◽  
2011 ◽  
Vol 18 (sup1) ◽  
pp. 157-159 ◽  
Author(s):  
L. H. Connors ◽  
G. Doros ◽  
F. Sam ◽  
A. Badiee ◽  
D. C. Seldin ◽  
...  
Keyword(s):  
Clinical Features ◽  
Systemic Amyloidosis ◽  
Senile Systemic Amyloidosis

Arterial thromboembolism in senile systemic amyloidosis: report of two cases

Amyloid ◽  
2012 ◽  
Vol 19 (2) ◽  
pp. 118-121 ◽  
Author(s):  
Michitaka Nakagawa ◽  
Kana Tojo ◽  
Yoshiki Sekijima ◽  
Kyo-hei Yamazaki ◽  
Shu-ichi Ikeda
Keyword(s):  
Systemic Amyloidosis ◽  
Arterial Thromboembolism ◽  
Senile Systemic Amyloidosis

scholarly journals A Case of a Senile Systemic Amyloidosis Patient Presenting With Angina Pectoris and Dilated Cardiomyopathy

2011 ◽  
Vol 41 (4) ◽  
pp. 209 ◽  
Author(s):  
Gu Hyun Kang ◽  
Dong Ryeol Ryu ◽  
Pil Sang Song ◽  
Young Bin Song ◽  
Joo-Yong Hahn ◽  
...  
Keyword(s):  
Angina Pectoris ◽  
Dilated Cardiomyopathy ◽  
Systemic Amyloidosis ◽  
Senile Systemic Amyloidosis

scholarly journals 103 Senile systemic amyloidosis: a common cause of heart failure in the elderly?

Heart ◽  
2011 ◽  
Vol 97 (Suppl 1) ◽  
pp. A59-A60
Author(s):  
J. H. Pinney ◽  
H. J. Lachmann ◽  
J. D. Gillmore ◽  
A. Wechalekar ◽  
S. D. J. Gibbs ◽  
...  
Keyword(s):  
Heart Failure ◽  
The Elderly ◽  
Systemic Amyloidosis ◽  
Common Cause ◽  
Senile Systemic Amyloidosis
Sign in / Sign up

Export Citation Format

Share Document